Abstract: The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water The compounds are present in the water at a concentration ranging from 0.

Abstract: The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.

Abstract: The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R, R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.

Abstract: Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: Provided is a disinfectant which is not harmful to the human body and has sterilizing power in atmospheric conditions. Liquid paraffin or Vaseline containing ozone is applied on the human body, or medical equipment to be disinfected is dipped therein. Thus, the disinfection of medical equipment is easily and conveniently achieved. When used on the human body, the disinfectant aids in the treatment of wounds because the disinfectant has a disinfection effect and a moisturizing effect.

Abstract: This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies.

Abstract: A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and polymeric species. The polymeric species may be in the form of a polymeric concentrate, such as, for example, polyaluminum chloride or polyferric sulfate. Alternatively, the polymeric species may be formed by partially neutralizing a metal salt. The aqueous solution of the metal astringent is applied to a lower leg and hoof area of an animal using any known application technique, including, but not limited to, foot baths, foams and spray applications. In preferred embodiments, the aqueous solution is applied using an automated dispensing system.

Abstract: A method for moisturizing the eye in which an amount of aqueous fluid is administered to the eye in an amount below that which causes flooding of the eye and removal of the normal tear film from the surface of the eye. The fluid, when administered in accordance with the invention, rehydrates the already present tear film rather than replacing the tear film. A kit for moisturizing the eye in accordance with the invention is also disclosed.

Abstract: Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.

Abstract: An aerosol composition comprising: 0.01 wt % to 1.00 wt % sodium borate; 0.01 wt % to 1.50 wt % polyglycerol ester surfactant; <30 wt % propellant; and 67.5 wt % to 85.0 wt % water. Methods of manufacture of an aerosol air freshener are also described wherein the aerosol composition further comprises a fragrance.

Abstract: Intranasally administering curcumin prodrugs and curcumin hybrids in a bolus of helium gas to the brain to treat Alzheimer's Disease

Abstract: Disclosed is an effervescent composition and a method of making an effervescent composition that includes a viscous component and is a free flowing granulation.

Abstract: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.

Abstract: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.

Abstract: Disclosed is an effervescent composition and a method of making an effervescent composition that includes a viscous component and is a free flowing granulation.

Abstract: The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a muscle relaxant, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% muscle relaxant degradation products. In a kit aspect of the present invention, a kit for delivering a muscle relaxant through an inhalation route is provided which comprises: a) a coating of a muscle relaxant and b) a device for dispensing said coating a muscle relaxant as a condensation aerosol.

Abstract: Provided, among other things, is a delivery module for a non-greasy, non-irritating selenium sulfide composition comprising: (A) an aerosol delivery device; (B) within the aerosol delivery device, the selenium sulfide composition comprising an effective amount of selenium sulfide that is 1% or more by weight of the composition, and a frothing agent, wherein the selenium sulfide composition has a viscosity low enough to support aerosol delivery and the selenium sulfide composition is effective to form a foam upon propellant-driven aerosol delivery; and (C) within the aerosol delivery device, a propellant.

Abstract: Disclosed herein is a pharmacophore model for arthropod repellent activity and methods of making and using thereof. The pharmacophore comprises two hydrophobic aliphatic functions, one aromatic function and one hydrogen bond acceptor function. The pharmacophore model was made using a test set of arthropod repellent compounds. Also disclosed are arthropod repellent compounds identified by screening databases with the pharmacophore model. Also disclosed are methods of repelling arthropods from a surface or area. Compositions and formulations comprising the compounds of the present invention as well as objects having the compounds of the present invention are disclosed.

Abstract: Liquid pharmaceutical compositions and kits for administration to the lungs comprise a carrier and an agent for the treatment of bronchoconstriction and asthma, wherein the agent comprises a derivative of dehydroepiandrosterone having an SO2H or SO2Na group. The liquid formulations can be administered as an aerosol.

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract: This invention related to methods of treating, preventing and managing various pulmonary or respiratory diseases or disorders using albuterol in combination with calcium activated potassium channel openers. Pharmaceuticals compositions comprising albuterol and calcium activated potassium channel openers are also disclosed.

Abstract: The present disclosure is directed towards administering a biologically effective amount of a thiomolybdate compound to a patient who demonstrates either depressive or aggressive behavior. According to the present disclosure, thiomolybdate compounds can be administered orally, sublingually, intravascular, intraperitoneal, intradermal, intramuscular, or via any other known administrative techniques. Administration of the thiomolybdate compound lowers the blood serum copper level in the patient, thereby reducing the efficacy of the copper levels which helped cause the onset or postpartum depression or aggression.

Abstract: Provided is an aerosol cosmetic composition containing, in a pressure container, a stock solution containing (A) 0.5 to 10 wt. % of a hair styling polymer, (B) 1 to 25 wt. % of a solvent having at least 2 hydroxy groups, having a molecular weight of 62 or greater but not greater than 1000 and being in the liquid form at 30° C., (C) 0.1 to 20 wt. % of a nonionic surfactant having an HLB of from 2.8 to 20 and being in the liquid form at 30° C. and/or N-acetyl ethanolamide, and (D) ethanol and/or water, and (B) a propellant, a weight ratio of the components (A)/(B) falling within a range of from 0.42 to 2.3. In the aerosol cosmetic composition of the present invention, hair is able to acquire a soft and light finish and moreover, can be re-styled.

Abstract: An aerosol composition comprising a propellant and a first particulate material comprising particles having a median aerodynamic diameter with the range 0.05 to 11 ?m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 ?m. The presence of the second particulate material provides good suspension properties, particularly where the propellant is a hydrofluoro alkane.

Abstract: A foam-like preparation in the form of an emulsion comprises a continuous phase, a discontinuous phase, and a gas, wherein the continuous phase comprises a thickening system being formed by the continuous phase and a thickening agent, and wherein the discontinuous phase comprises a structuring agent, wherein the thickening system has a miscibility gap with a lower critical temperature which is above the use temperature of the preparation.

Abstract: Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity.

Abstract: A sprayable air-freshening composition comprising active particles for removing malodours, said active particles comprising at least one metal supported on a solid particulate support, wherein the at least one metal is selected from Groups 3 to 12 and the Lanthanide series of the periodic table.

Abstract: A spray delivery system in combination with a scalp medication is provided which includes a portable container having a gas imperious container wall, a pressure source disposed within the container, and a selectively operable valve assembly affixed to the container. The scalp medication is in liquid form and is disposed within the container. The scalp medication comprises a hair growth stimulation or hair growth maintenance active ingredient in an amount sufficient to stimulate or maintain hair growth disposed within a pharmacologically acceptable carrier solution. The valve assembly of the system produces a 1 mL spray of said scalp medication within about 5 seconds following a single operation of said valve assembly. A method of treating alopecia using a continuous spray employing such a system is also provided. Both bag-on-valve (bag-in-can) and metered dose packages are disclosed.

Abstract: A formula for use in treating skin aliments includes from about 20 to about 75 wt % emu oil; from about 0.10 to 33 wt % benzyl alcohol; from about 0.10 to about 33 wt % benzoin derivative; from about 0.2 to about 2 wt % allantoin; from about 0.25 to about 1.25 wt % methylparaben; from about 1.0 to about 13 wt % alkyl esters; and from about 0.01 to about 0.30 wt % propylparaben. The formula can be applied to skin of animals or humans with skin ailments. The formula can be applied is various manners, such as through an enhanced oil, a spray, an elastomeric device, a wipe, a lotion, an ointment, a cream, a gel or combinations thereof.

Abstract: Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.

Abstract: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.

Abstract: An ingestible particulate composition comprises: a. an alginate and/or alginic acid; b. a bicarbonate and/or carbonate; c. an organic acid; and d. an agglomerant, being a compound, such as a low molecular weight polyol, which allows the particulate composition to flow yet which substantially does not release fine particulates into the air. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for administration direction into a patient's mouth, and ingested to alleviate oesophageal and gastric conditions.

Abstract: A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon ?, interferon ? or interferon ? in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.

Abstract: A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.

Abstract: An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline and nebulized into an aerosol having a mass median aerodynamic diameter 3 ?m to 10 ?m and a geometric standard deviation less than 1.7 using an electronic nebulizer.

Abstract: Particulate formulations of benzodiazepines, such as diazepam, are used for nasal administration of diazepine drugs to patients. Multimodal particulate formulations of benzodiazepines and methods for their use, e.g. by nasal administration for the treatment of seizure, are also provided.

Abstract: A foam is described for injection treatment of varicose veins. The foam comprises a sclerosant liquid, e.g. polidocanol solution, and a gas. The gas comprises xenon, optionally together with at least one other physiologically acceptable gas which is readily absorbed in the body or blood of a patient. The gas comprises only a minimal amount of gaseous nitrogen, between 0.0001% and 0.8%.

Abstract: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.

Abstract: A medicament comprising, separately or together (A) glycopyrrolate; and (B) either a compound of formula I in free or salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification, or a compound of formula II in free or salt or solvate form, wherein X has the meaning as indicated in the specification, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain (A) and (B) are also described.

Abstract: Methods for the manufacture of medicinal compositions are described. A method for the manufacture of a medicinal composition according to the invention comprises: (a) Providing a biocompatible polymer of the general formula —[O—R1—C(O)]n— wherein: “R1” is a linear, branched, or cyclic organic group, “n” is at least three, (b) Acylating the biocompatible polymer to provide an acylated biocompatible polymer and a mixed anhydride; (c) Reacting the mixed anhydride with a nucleophile to provide an acylated biocompatible polymer with a terminal carboxylic acid derivative capable of being chemically converted to an acid in the absence of water, (d) Converting the terminal carboxylic acid derivative to an acylated biocompatible polymer with a terminal carboxylic acid; and (e) Combining the acylated biocompatible polymer with a drug to provide the medicinal composition.

Abstract: This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical, therapeutic and cosmetic compositions, comprising an active agent, having a sensation or sensation modifying affect on a body surface, upon application. More particularly, the invention relates to foamable compositions comprising: (a) a foamable carrier; (b) at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; stimulating or refreshing agent; or mixtures thereof and (c) a propellant at a concentration of about 3% to about 45% by weight of the total composition. The foamable carrier can be an emollient emulsion foamable vehicle, a foamable gel vehicle and can also be a substantially non aqueous foamable vehicle.

Abstract: Improved aqueous foaming topical compositions for the application to the human body particularly to the skin which composition provides both a cleaning benefit, and a durable antimicrobial benefit.

Abstract: The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

Abstract: The present invention includes compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream.

Abstract: Cosmetic and/or pharmaceutical preparations comprising (a) a carbonate of the formula (I): wherein R1 is a linear alkyl and/or alkenyl group having from 6 to 22 carbon atoms, a 2-ethylhexyl, isotridecyl or isostearyl group or a group derived from a polyol having from 2 to 15 carbon atoms and at least two hydroxyl groups; R2 has the same meaning as R1 or is an alkyl group having from 1 to 5 carbon atoms and each of n and m independently has a value of from 0 to 100; and (b) a propellant can be used as aerosols.

Abstract: A method of administering a drug whereby a fine drug powder can be accurately administered to a target site (in particular, a target site in the body cavity) via fluidization and spraying with a gas by using a micro tube. Concerning the administration mode, in particular, the drug alone or a biopolymer is administered or the biopolymer is employed as a carrier in the above method. More specifically speaking, a method of administering a fine drug powder which comprises finely milling one or more types fine particles of the drug and/or the biopolymer, blending them each other, fluidizing the blend with a gas, then transporting the fluidized matter in a micro tube by the gas stream and spraying the fine drug powder from the tip of the micro tube toward the target site.

Abstract: A pharmaceutical formulation for delivery in aerosol or spray form, comprising a liquefied propellant gas, a solid particulate pharmaceutically active agent and a dispersing agent, wherein the dispersing agent is fused to the surface of particles of the pharmaceutically active agent.

Abstract: Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material, wherein the composition or article does not contain an antiperspirant active.

Abstract: The present invention relates to cosmetic and pharmaceutical compositions which comprise a copolymer with anionogenic and/or anionic groups which is obtainable by free-radical polymerization of a monomer mixture in the presence of a polyfunctional regulator with at least three functional regulating groups. The invention further relates to a method of producing such a copolymer and to the copolymers obtainable by this method.